Status: Recruiting
Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia
This is a multicenter, randomized, double-blind, placebo-controlled parallel-group trial to evaluate the safety, tolerability, preliminary efficacy and PK characteristics of multiple doses of LPM3770164 sustained-release tablets in TD patients.
Participants needed: 120
Trial details
Phase: Phase 1, Phase 2Age: 18-64Biological sex: AllType: InterventionalSponsor: Luye Pharma Group Ltd.Updated: Jan 22, 2025Locations: 1
Eligibility criteria
Subject who voluntarily participate in and sign the informed consent form; [+6]
Has comorbid abnormal involuntary movement(s) that is more prominent than TD as... [+24]